The first data on a likely anti-CD200 treatment in neoplastic diseases come from hematologic malignancies where it has been demonstrated that CD200 blockade may represent a novel approach to clinical treatment of CLL [79]. This evidence concerns the gene CD200 and hematologic disorder.